Article
Novel FLT3 tyrosine kinase inhibitors.
Expert opinion on investigational drugs - 1 Dec 2003
Levis Mark, Small Donald
Abstract excerpt
Acute myeloid leukaemia (AML) is an aggressive haematological malignancy that is curable in approximately 40% of cases. Activating mutations of the receptor tyrosine kinase FLT3 (FMS-like tyrosine kinase-3) are the single most common molecular abnormalities in AML and are associated with a distinctly worse prognosis. In an effort to target this mutation and improve outcomes in this subgroup of AML patients,...
Topics
- Animals
- Antineoplastic Agents
- Clinical Trials as Topic
- Enzyme Inhibitors
- Humans
- Mutation
- Proto-Oncogene Proteins
- Receptor Protein-Tyrosine Kinases
- fms-Like Tyrosine Kinase 3